These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10335757)

  • 21. Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.
    Hunninghake D; Insull W; Knopp R; Davidson M; Lohrbauer L; Jones P; Kafonek S
    Am J Cardiol; 2001 Sep; 88(6):635-9. PubMed ID: 11564386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment.
    Farnier M
    Am J Cardiol; 1998 Aug; 82(4B):47J-51J. PubMed ID: 9737646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia. Hyperlipidaemia in Diabetes Mellitus investigators.
    Rubinstein A; Maritz FJ; Soule SG; Markel A; Chajek-Shaul T; Maislos M; Tal S; Stolero D
    J Cardiovasc Risk; 1999 Dec; 6(6):399-403. PubMed ID: 10817086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
    Stein EA
    Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers.
    Mazzu A; Lettieri J; Kaiser L; Mullican W; Heller AH
    J Clin Pharmacol; 1998 Aug; 38(8):715-9. PubMed ID: 9725547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
    Balletshofer BM; Goebbel S; Rittig K; Enderle M; Schmölzer I; Wascher TC; Ferenc Pap A; Westermeier T; Petzinna D; Matthaei S; Häring HU
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):324-30. PubMed ID: 15977099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.
    Mazzu AL; Lettieri JT; Kelly E; Vargas R; Marbury T; Liu MC; Sundaresan P
    Eur J Clin Pharmacol; 2000 Apr; 56(1):69-74. PubMed ID: 10853881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ochmann K; Rohde G; Unger S; Kuhlmann J
    Eur J Clin Pharmacol; 1998 Feb; 53(6):469-73. PubMed ID: 9551706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
    Weber P; Lettieri JT; Kaiser L; Mazzu AL
    Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacy clinics. Medication of the month. Cerivastatin (Lipobay, Cholstat)].
    Scheen AJ
    Rev Med Liege; 2000 Feb; 55(2):117-20. PubMed ID: 10769583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness.
    McPherson R; Hanna K; Agro A; Braeken A;
    Clin Ther; 2001 Sep; 23(9):1492-507. PubMed ID: 11589262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerivastatin.
    McClellan KJ; Wiseman LR; McTavish D
    Drugs; 1998 Mar; 55(3):415-20; discussion 421-2. PubMed ID: 9530546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
    Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
    Mück W; Park S; Jäger W; Voith B; Wandel E; Galle PR; Schwarting A
    Int J Clin Pharmacol Ther; 2001 May; 39(5):192-8. PubMed ID: 11380064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.
    Isaacsohn J; Zinny M; Mazzu A; Lettieri J; Heller AH
    Eur J Clin Pharmacol; 2001 Mar; 56(12):897-903. PubMed ID: 11317478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
    Bischoff H; Angerbauer R; Boberg M; Petzinna D; Schmidt D; Steinke W; Thomas G
    Atherosclerosis; 1998 Sep; 139 Suppl 1():S7-13. PubMed ID: 9811153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.
    Tazuma S; Yamashita G; Ochi H; Miura H; Kajihara T; Hattori Y; Miyake H; Nishioka T; Hyogo H; Sunami Y; Yasumiba S; Kajiyama G
    Clin Ther; 1998; 20(3):477-85. PubMed ID: 9663363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
    Ridker PM; Rifai N; Lowenthal SP
    Circulation; 2001 Mar; 103(9):1191-3. PubMed ID: 11238259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
    Mabuchi H; Koizumi J; Kajinami K
    Am J Cardiol; 1998 Aug; 82(4B):52J-55J. PubMed ID: 9737647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.